<p>公司们经常宣布股票拆分，而截至目前，今年已经有多家知名公司将其股票拆分成更小的份额。</p>
<p><strong>沃尔玛</strong> (NYSE:WMT) 在二月份进行了股票拆分，<strong>墨西哥卷饼餐厅</strong> (NYSE:CMG) 在六月份进行了 <strong>纽约证券交易所</strong> 历史上最大的拆分，拆分比例为 50 比 1，而 <strong>英伟达</strong> (NASDAQ:NVDA) 在一个月后进行了 4 比 1 的拆分。</p>
<p>虽然有几家公司可能会在下一个股票拆分公告中脱颖而出，但 <strong>Vertex Pharmaceuticals</strong> (NASDAQ:VRTX) 可能会在 11 月 4 日的财报中超越它们。</p>
<h2>24/7 Wall St. 见解：</h2>
<ul>
<li><strong>Vertex Pharmaceuticals</strong> (VRTX) 在囊性纤维化市场几乎拥有垄断地位，提供两种疗法，治疗约 75% 的患者。</li>
<li>由于 VRTX 股票的交易价格为每股 475 美元，远高于更大的竞争对手，这家生物技术公司可能会选择让其股票对投资者更具可及性。</li>
<li>如果你在寻找一些具有巨大潜力的股票，确保获取我们全新的 “下一个英伟达” 报告的免费副本。报告中介绍了一只我们相信具有 10 倍潜力的软件股票。</li>
</ul>
<h2>更小的蛋糕切片</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2020/08/imageForEntry1-Vx1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2020/08/imageForEntry1-Vx1.jpg"/></p>
<p>尽管股票拆分被视为看涨信号，但这并不意味着投资者不需要进行尽职调查。</p>
<p>股票拆分当然是企业的非事件。因为它们只是改变了流通股数量和股价，对公司的基本面没有实际影响。</p>
<p>然而，投资者对此情有独钟！管理层将其视为未来增长的看涨信号，并通过人为降低股价，让更多投资者有机会购买。</p>
<p>有一些证据表明这一点。以往股票拆分的数据表明，公司在事件发生后的 12 个月内增长了 25% 到 30%。但拆分只是反映了强劲的过去表现，并没有创造任何新的股东价值。投资者仍需仔细审查业务，以确保其将保持在同一轨迹上。</p>
<p>例如，本月早些时候，<strong>超微计算机</strong> (NASDAQ:SMCI) 完成了 10 比 1 的股票拆分。拆分前交易接近 416 美元的股票，现在的价格为每股 41.60 美元。然而，SMCI 在公告前的交易价格已超过 600 美元，但令人失望的财报、空头报告指出潜在的会计不规范，以及司法部对其会计实践的调查消息，都使其股价大幅下跌。</p>
<p>而现在，其会计事务所安永已辞职，表示不想再接手超微的账簿。该消息使股价再次暴跌 33%。SMCI 的股价自 3 月高点以来已下跌 73%。股票拆分并不总是意味着好消息。</p>
<h2>小池塘里的大鱼</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2019/12/imageforentry12-0wh.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2019/12/imageforentry12-0wh.jpg"/></p>
<p>Vertex Pharmaceuticals 是治疗囊性纤维化的无可争议的领导者。</p>
<p>Vertex Pharmaceuticals 并未面临类似的丑闻。这家生物技术公司在过去三年中上涨了 162%，其在囊性纤维化治疗中的几乎垄断地位持续推动着其业务增长。</p>
<p>在北美、欧洲和澳大利亚估计有 92,000 名囊性纤维化患者，Vertex 治疗了近四分之三的患者。其主要疗法 Trikafta 和 Kaftrio 在 2024 年上半年产生了 49 亿美元的销售额，比去年同期增长了 14%。这两种药物占 Vertex 总收入的 92%。</p>
<p>这家生物技术公司的风险在于其定义过于狭窄。由于专注于单一疾病，且所有销售依赖于一两种药物，若竞争对手开发出新的、更好的治疗方案，集中风险将加大。</p>
<p>这就是为什么 Vertex 希望拓宽视野，进入罕见疾病药物市场。它与 <strong>CRISPR Therapeutics</strong> (NASDAQ:CRSP) 合作，帮助基因编辑疗法 Casgevy 于去年 12 月获得食品和药物管理局的批准，用于治疗输血依赖性β-地中海贫血（TDT）和镰状细胞病（SCD）。该药物具有十亿美元的潜在市场。</p>
<p>虽然 CRISPR 将获得 Casgevy 利润的绝大部分，但 Vertex 将获得 40% 的利润。它还将获得 40% 的研发费用的报销。</p>
<h2>行动时刻</h2>
<p>VRTX 的股票交易价格为每股 475 美元，过去一年上涨了 33%。现在进行股票拆分可能是合理的，以增加其流动性，并通过缩小买卖差价来实现生物技术公司股票的更有效定价。</p>
<p>随着股票对更广泛的投资者群体变得更加可及，可能会提升其交易量。</p>
<p>Vertex Pharmaceuticals 并不陌生于股票拆分，尽管自上次拆分以来已经过去很长时间。这家生物技术公司今天与 2000 年进行 2 比 1 拆分时相比，已经大为不同。</p>
<p>凭借强大的、盈利的囊性纤维化业务、在新市场的潜在增长、丰富的临床试验疗法管道，以及远超 <strong>安进</strong> (NASDAQ:AMGN) 和 <strong>生物基因</strong> (NASDAQ:BIIB) 的股价，VRTX 可能成为下一个进行股票拆分的公司。</p>
<h2><strong>投资的基本技巧（赞助）</strong></h2>
<p>财务顾问可以帮助你了解投资物业的优缺点。寻找合格的财务顾问并不困难。SmartAsset 的免费工具可以将你与最多三位服务于你所在地区的财务顾问匹配，你可以免费面试这些顾问，以决定哪个最适合你。如果你准备找到一位可以帮助你实现财务目标的顾问，现在就开始吧。</p>
<p>投资房地产可以使你的投资组合多样化。但拓宽视野可能会增加额外成本。如果你是希望降低开支的投资者，可以考虑查看在线经纪公司。它们通常提供低投资费用，帮助你最大化利润。</p>
<p>预测：福泰制药 (VRTX) 可能成为下一个拆股股票，首发于 24/7 Wall St..</p>

福泰制药

<p>Vertex Pharmaceuticals (VRTX) 被预测为可能进行股票拆分的候选者，特别是在它于 11 月 4 日发布财报之际。该公司在囊性纤维化市场中占据强势地位，约 75% 的患者使用其领先的治疗方案。尽管股票拆分通常被视为看涨信号，但并不会改变公司的基本面。VRTX 在过去三年中实现了 162% 的显著增长，但由于其对囊性纤维化治疗的狭窄关注，面临一定风险。该公司还通过与 CRISPR Therapeutics 的合作，探索在罕见疾病市场的机会</p>

<p>Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices.</p>
<div class="lb-trans"><p>公司们经常宣布股票拆分，而截至目前，今年已经有多家知名公司将其股票拆分成更小的份额。</p>
</div><p><strong>Walmart</strong> (NYSE:WMT) split its stock in February, <strong>Chipotle Mexican Grill</strong> (NYSE:CMG) did the largest split in <strong>NYSE</strong> history in June when it split its shares 50-to-1, and <strong>Nvidia</strong> (NASDAQ:NVDA) split its stock 4-to-1 a month later.</p>
<div class="lb-trans"><p><strong>沃尔玛</strong> (NYSE:WMT) 在二月份进行了股票拆分，<strong>墨西哥卷饼餐厅</strong> (NYSE:CMG) 在六月份进行了 <strong>纽约证券交易所</strong> 历史上最大的拆分，拆分比例为 50 比 1，而 <strong>英伟达</strong> (NASDAQ:NVDA) 在一个月后进行了 4 比 1 的拆分。</p>
</div><p>While there are several candidates to make the next stock split announcement, <strong>Vertex Pharmaceuticals</strong> (NASDAQ:VRTX) may just trump them all when it reports earnings on Nov. 4.</p>
<div class="lb-trans"><p>虽然有几家公司可能会在下一个股票拆分公告中脱颖而出，但 <strong>Vertex Pharmaceuticals</strong> (NASDAQ:VRTX) 可能会在 11 月 4 日的财报中超越它们。</p>
</div><h2>24/7 Wall St. Insights:</h2>
<ul>
<li><strong>Vertex Pharmaceuticals</strong> (VRTX) has a virtual monopoly on the cystic fibrosis market with two therapies treating about 75% of all patients.</li>
<li>With VRTX stock trading at $475 per share, well ahead of even larger rivals, the biotech may choose to make its shares more accessible to investors.</li>
<li>If you’re looking for some stocks with huge potential, make sure to grab a free copy of our brand-new “The Next NVIDIA” report. It features a software stock we’re confident has 10X potential.</li>
</ul>
<div class="lb-trans"><h2>24/7 Wall St. 见解：</h2>
<ul>
<li><strong>Vertex Pharmaceuticals</strong> (VRTX) 在囊性纤维化市场几乎拥有垄断地位，提供两种疗法，治疗约 75% 的患者。</li>
<li>由于 VRTX 股票的交易价格为每股 475 美元，远高于更大的竞争对手，这家生物技术公司可能会选择让其股票对投资者更具可及性。</li>
<li>如果你在寻找一些具有巨大潜力的股票，确保获取我们全新的 “下一个英伟达” 报告的免费副本。报告中介绍了一只我们相信具有 10 倍潜力的软件股票。</li>
</ul>
</div><h2>Smaller slices of the pie</h2>
<div class="lb-trans"><h2>更小的蛋糕切片</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2020/08/imageForEntry1-Vx1.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2020/08/imageForEntry1-Vx1.jpg"/></p>
<p>Just because a stock split is seen as a bullish signal doesn’t mean investors don’t need to still perform their due diligence</p>
<div class="lb-trans"><p>尽管股票拆分被视为看涨信号，但这并不意味着投资者不需要进行尽职调查。</p>
</div><p>Stocks splits, of course, are a corporate non-event. Because they only change the number of shares outstanding — and the stock price — there is no real impact on the underlying fundamentals of the company.</p>
<div class="lb-trans"><p>股票拆分当然是企业的非事件。因为它们只是改变了流通股数量和股价，对公司的基本面没有实际影响。</p>
</div><p>Yet investors love them! They are viewed as a bullish signal by management that more growth is on the way and by artificially lowering the share price, more investors will have an opportunity to buy them.</p>
<div class="lb-trans"><p>然而，投资者对此情有独钟！管理层将其视为未来增长的看涨信号，并通过人为降低股价，让更多投资者有机会购买。</p>
</div><p>There is some evidence this is true. Data from previous stock splits suggests companies grow between 25% and 30% in the 12 months after the event. But a split is only reflecting strong past performance and not creating any new shareholder value. Investors still need to scrutinize the business to ensure it will remain on the same trajectory.</p>
<div class="lb-trans"><p>有一些证据表明这一点。以往股票拆分的数据表明，公司在事件发生后的 12 个月内增长了 25% 到 30%。但拆分只是反映了强劲的过去表现，并没有创造任何新的股东价值。投资者仍需仔细审查业务，以确保其将保持在同一轨迹上。</p>
</div><p>For example, earlier this month <strong>Super Micro Computer</strong> (NASDAQ:SMCI) completed a 10-for-1 stock split. Shares that had been trading near $416 pre-split were now going for $41.60 per share. Yet SMCI had been trading well north of $600 a share prior to the announcement, but disappointing earnings, a short-seller’s report calling out potential accounting irregularities, and news of a Justice Dept. probe into its accounting practices all sent its shares careening lower.</p>
<div class="lb-trans"><p>例如，本月早些时候，<strong>超微计算机</strong> (NASDAQ:SMCI) 完成了 10 比 1 的股票拆分。拆分前交易接近 416 美元的股票，现在的价格为每股 41.60 美元。然而，SMCI 在公告前的交易价格已超过 600 美元，但令人失望的财报、空头报告指出潜在的会计不规范，以及司法部对其会计实践的调查消息，都使其股价大幅下跌。</p>
</div><p>And now its accounting firm EY has resigned saying it doesn’t want to touch Super Micro’s books anymore. The stock tanked another 33% on the news. SMCI stock is down 73% from its March peak. Stock splits don’t always mean good news.</p>
<div class="lb-trans"><p>而现在，其会计事务所安永已辞职，表示不想再接手超微的账簿。该消息使股价再次暴跌 33%。SMCI 的股价自 3 月高点以来已下跌 73%。股票拆分并不总是意味着好消息。</p>
</div><h2>The big fish in a small pond</h2>
<div class="lb-trans"><h2>小池塘里的大鱼</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2019/12/imageforentry12-0wh.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2019/12/imageforentry12-0wh.jpg"/></p>
<p>Vertex Pharmaceuticals is the undisputed leader in treating cystic fibrosis</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals 是治疗囊性纤维化的无可争议的领导者。</p>
</div><p>Vertex Pharmaceuticals isn’t facing any similar scandals. The biotech is up 162% over the past three years as its virtual monopoly on cystic fibrosis treatment continues driving its business higher.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals 并未面临类似的丑闻。这家生物技术公司在过去三年中上涨了 162%，其在囊性纤维化治疗中的几乎垄断地位持续推动着其业务增长。</p>
</div><p>Of the estimated 92,000 patients with CF in North America, Europe and Australia, Vertex treats nearly three-quarters of them. Its leading therapies are Trikafta and Kaftrio that have generated $4.9 billion in sales in the first half of 2024, a 14% increase over the year-ago period. The duo account for 92% of Vertex’s total revenue.</p>
<div class="lb-trans"><p>在北美、欧洲和澳大利亚估计有 92,000 名囊性纤维化患者，Vertex 治疗了近四分之三的患者。其主要疗法 Trikafta 和 Kaftrio 在 2024 年上半年产生了 49 亿美元的销售额，比去年同期增长了 14%。这两种药物占 Vertex 总收入的 92%。</p>
</div><p>The risk for the biotech comes in being so narrowly defined. By being laser-focused on a single condition, and having all of its sales dependent upon one or two drugs, the concentration risk is heightened in the event a rival develops a new, better treatment.</p>
<div class="lb-trans"><p>这家生物技术公司的风险在于其定义过于狭窄。由于专注于单一疾病，且所有销售依赖于一两种药物，若竞争对手开发出新的、更好的治疗方案，集中风险将加大。</p>
</div><p>That’s why Vertex is looking to broaden its outlook to enter the rare disease drug market. It has partnered with <strong>CRISPR Therapeutics</strong> (NASDAQ:CRSP), which helped get the gene-editing therapy Casgevy approved by the Food &amp; Drug Administration last December for the treatment of transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD). It has billion-dollar blockbuster potential.</p>
<div class="lb-trans"><p>这就是为什么 Vertex 希望拓宽视野，进入罕见疾病药物市场。它与 <strong>CRISPR Therapeutics</strong> (NASDAQ:CRSP) 合作，帮助基因编辑疗法 Casgevy 于去年 12 月获得食品和药物管理局的批准，用于治疗输血依赖性β-地中海贫血（TDT）和镰状细胞病（SCD）。该药物具有十亿美元的潜在市场。</p>
</div><p>While CRISPR will receive the lion’s share of the profits for Casgevy, Vertex will get 40% of them. It also gets reimbursed for 40% of the research and development costs that went into the drug.</p>
<div class="lb-trans"><p>虽然 CRISPR 将获得 Casgevy 利润的绝大部分，但 Vertex 将获得 40% 的利润。它还将获得 40% 的研发费用的报销。</p>
</div><h2>Time for action</h2>
<div class="lb-trans"><h2>行动时刻</h2>
</div><p>Shares of VRTX trade $475 each, up 33% over the past year. A stock split could make sense now to increase its liquidity and allow for more efficient pricing of the biotech’s shares by narrowing the bid-ask price.</p>
<div class="lb-trans"><p>VRTX 的股票交易价格为每股 475 美元，过去一年上涨了 33%。现在进行股票拆分可能是合理的，以增加其流动性，并通过缩小买卖差价来实现生物技术公司股票的更有效定价。</p>
</div><p>As the stock becomes more accessible to a broader range of investors, it has the potential to boost its trading volume.</p>
<div class="lb-trans"><p>随着股票对更广泛的投资者群体变得更加可及，可能会提升其交易量。</p>
</div><p>Vertex Pharmaceuticals isn’t a stranger to splitting its stock, though it is a long time since the last split occurred. The biotech is a much different company today than it was in 2000 when it split its shares 2-for-1.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals 并不陌生于股票拆分，尽管自上次拆分以来已经过去很长时间。这家生物技术公司今天与 2000 年进行 2 比 1 拆分时相比，已经大为不同。</p>
</div><p>With a strong, profitable CF business, potential growth in new markets, a robust pipeline of therapies in clinical trials, and a stock price well ahead of rivals like <strong>Amgen</strong> (NASDAQ:AMGN) and <strong>Biogen</strong> (NASDAQ:BIIB), VRTX could be the next stock split stock.</p>
<div class="lb-trans"><p>凭借强大的、盈利的囊性纤维化业务、在新市场的潜在增长、丰富的临床试验疗法管道，以及远超 <strong>安进</strong> (NASDAQ:AMGN) 和 <strong>生物基因</strong> (NASDAQ:BIIB) 的股价，VRTX 可能成为下一个进行股票拆分的公司。</p>
</div><h2><strong>Essential Tips for Investing (Sponsored)</strong></h2>
<div class="lb-trans"><h2><strong>投资的基本技巧（赞助）</strong></h2>
</div><p>A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.</p>
<div class="lb-trans"><p>财务顾问可以帮助你了解投资物业的优缺点。寻找合格的财务顾问并不困难。SmartAsset 的免费工具可以将你与最多三位服务于你所在地区的财务顾问匹配，你可以免费面试这些顾问，以决定哪个最适合你。如果你准备找到一位可以帮助你实现财务目标的顾问，现在就开始吧。</p>
</div><p>Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.</p>
<div class="lb-trans"><p>投资房地产可以使你的投资组合多样化。但拓宽视野可能会增加额外成本。如果你是希望降低开支的投资者，可以考虑查看在线经纪公司。它们通常提供低投资费用，帮助你最大化利润。</p>
</div><p>The post Prediction: Vertex Pharmaceuticals (VRTX) Could Be The Next Stock Split Stock appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>预测：福泰制药 (VRTX) 可能成为下一个拆股股票，首发于 24/7 Wall St..</p>
</div>

预测：福泰制药（VRTX）可能是下一个进行股票拆分的公司